News | February 05, 2025
Pfizer reports 2024 revenues 7% higher at $63.6 billion
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
The company remains focused on strengthening its direct retail presence and expanding its reach to more customers across India.
Novel illumination system with key components molded in Radel® PPSU for durability and repeated sterilization
Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
Subscribe To Our Newsletter & Stay Updated
